Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-1101 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ONO-1101 | DRUG | - |
Inclusion Criteria: 1. 20-80 years old 2. Postoperative supraventricular tachyarrhythmias (sinus tachycardia, those with a heart rate of 120 beats/min or higher, and supraventricular arrhythmia, those with a heart rate of 100 beats/min or higher) 3. Within 7 days postoperatively 4. Other inclusion ...
ONO-1101 is an investigational small molecule being studied for the treatment of postoperative supraventricular tachyarrhythmia, a condition of abnormally fast heart rhythms that can occur after surgery. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ONO-1101 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker symbol BWAY. The drug is in Phase 2 clinical development for postoperative supraventricular tachyarrhythmia.
ONO-1101 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed for the treatment of postoperative supraventricular tachyarrhythmia.
ONO-1101 has one completed Phase 2 clinical trial, identified as NCT00212680, titled "Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan." The trial enrolled 100 participants aged 21 years and older with postoperative supraventricular tachyarrhythmia.
ONO-1101 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for postoperative supraventricular tachyarrhythmia. The drug has completed one Phase 2 clinical trial, but it has not yet received regulatory approval.